Psycheceutical Bioscience, with a valuation of $135.29 million, is raising funds on Wefunder. The company is developing two patented delivery technologies to make psychedelics more safe and efficient. Psycheceutical Bioscience aims to provide safer psychedelic medicines for better mental health treatments and has collected observational data to show its technology led to symptom relief in 80% of the patients. Also, the phase one trial results of ketamine topical for PTSD have shown to be safe and well-tolerated. Chad Harman founded Psycheceutical Bioscience in June 2004. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for public filing expenses, strategic transactions and business development initiatives, corporate administration, and general working capital purposes.